Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

NCT04464642 is registered in ClinicalTrials.gov with Dr. Mohammad Mamun Khan as lead sponsor.

NCT NCT04464642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis
Lead sponsor
Dr. Mohammad Mamun Khan
Phase
Phase 4
Overall status
Unknown status
Start date
July 10, 2019
Completion date
September 30, 2020
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis